Vivo Capital’s ALX Oncology ALXO Stock Holding History

Vivo Capital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.39M	Buy	+3,184,713	New	+$6.07M	0.53%	35
2024 Q4	–	Sell	-4,034,522	Closed	-$7.34M	–	42
2024 Q3	$7.34M	Sell	4,034,522 -185,526	-4%	-$690K	0.61%	27
2024 Q2	$25.4M	Hold	4,220,048	–	–	2.35%	9
2024 Q1	$47.1M	Hold	4,220,048	–	–	3.7%	7
2023 Q4	$62.8M	Hold	4,220,048	–	–	5.14%	5
2023 Q3	$20.3M	Hold	4,220,048	–	–	2.22%	14
2023 Q2	$31.7M	Hold	4,220,048	–	–	2.19%	11
2023 Q1	$19.1M	Hold	4,220,048	–	–	1.32%	16
2022 Q4	$47.6M	Hold	4,220,048	–	–	5.48%	4
2022 Q3	$40.4M	Hold	4,220,048	–	–	4.46%	5
2022 Q2	$34.1M	Hold	4,220,048	–	–	3.43%	6
2022 Q1	$71.3M	Hold	4,220,048	–	–	4.91%	6
2021 Q4	$90.7M	Hold	4,220,048	–	–	5.47%	5
2021 Q3	$312M	Hold	4,220,048	–	–	14%	1
2021 Q2	$231M	Hold	4,220,048	–	–	9.99%	2
2021 Q1	$311M	Hold	4,220,048	–	–	10.94%	2
2020 Q4	$364M	Hold	4,220,048	–	–	16.23%	1
2020 Q3	$159M	Buy	+4,220,048	New	+$166M	9.2%	2

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vivo Capital's ALXO Position: Q1 2026 in Review

Vivo Capital opened a new position in ALX Oncology (ALXO) in Q1 2026: 3,184,713 shares worth $6.39M. The stake represents 0.53% of the portfolio and ranks #35 among its holdings. This is a return to the name: Vivo Capital previously reported a position in ALXO as recently as Q3 2024.

Vivo Capital first reported a position in ALXO in Q3 2020 and has held it in 18 quarters since. The position peaked at $364M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Vivo Capital held 3,184,713 shares of ALX Oncology worth $6.39M as of Q1 2026.
ALX Oncology was a new Vivo Capital position in Q1 2026.
ALX Oncology made up 0.53% of Vivo Capital's portfolio in Q1 2026, its #35 holding.
Vivo Capital first reported a position in ALX Oncology in Q3 2020 and has held it in 18 quarters since.
Vivo Capital's ALX Oncology position peaked at $364M in Q4 2020.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.